You can buy or sell Moderna and other stocks, options, and ETFs commission-free!
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA. The listed name for MRNA is Moderna, Inc. Common Stock.
52 Week High
52 Week Low
Jack Kramer & Nick MartellManaging Editors of News & Snacks at Robinhood Financial LLC
UK secures 2 million more doses of Moderna's Covid vaccine
Researchers work in a lab run by Moderna Inc, who said November 16, 2020 that its experimental vaccine was 94.5% effective in preventing COVID-19 based on inter
Moderna Inc. stock outperforms competitors on strong trading day
Shares of Moderna Inc. MRNA, +16.34% climbed 16.35% to $127.03 Friday, on what proved to be an all-around favorable trading session for the stock market, with t
— per share
Expected Feb 24, Pre-Market
Sweden's Recipharm signs deal to package Moderna's COVID-19 vaccine
FILE PHOTO: Coronavirus: On November 16, 2020, US biotech company Moderna announced a vaccine against COVID-19 that is 94.5% effective. Montreal, November 16, 2